[15] A transdermal formulation of asenapine was approved in the United States in October 2019 under the brand name Secuado.

[10] As for its efficacy in the treatment of acute mania, a recent meta-analysis showed that it produces comparatively small improvements in manic symptoms in patients with acute mania and mixed episodes than most other antipsychotic drugs such as risperidone and olanzapine (with the exception of ziprasidone).

[17] According to a post-hoc analysis of two 3-week clinical trials it may possess some antidepressant effects in patients with acute mania or mixed episodes.

[21] Its potential for elevating plasma prolactin levels seems relatively limited too according to this meta-analysis.

[21] For all antipsychotics, the British National Formulary recommends a gradual dose reduction when discontinuing to avoid acute withdrawal syndrome or rapid relapse.

[23] There is tentative evidence that discontinuation of antipsychotics can result in psychosis as a transient withdrawal symptom.